Portal de Periódicos da CAPES

Clinical significance of soluble interleukin 2 receptor for monitoring the diseases associated with activated lymphocytes and viral infections

1992; Wiley; Volume: 6; Issue: 6 Linguagem: Inglês

10.1002/jcla.1860060615

1098-2825

Tadashi Obara, Morton A. Vodian, Patrick C. Kung,

Cytomegalovirus and herpesvirus research

Journal of Clinical Laboratory AnalysisVolume 6, Issue 6 p. 423-436 Original Article Clinical significance of soluble interleukin 2 receptor for monitoring the diseases associated with activated lymphocytes and viral infections Dr. Tadashi Obara, Corresponding Author Dr. Tadashi Obara Diagnostic R&D Department, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JapanDiagnostic R&D Department, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JapanSearch for more papers by this authorMorton A. Vodian, Morton A. Vodian T Cell Sciences, Inc., Cambridge, MassachusettsSearch for more papers by this authorPatrick C. Kung, Patrick C. Kung T Cell Sciences, Inc., Cambridge, MassachusettsSearch for more papers by this author Dr. Tadashi Obara, Corresponding Author Dr. Tadashi Obara Diagnostic R&D Department, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JapanDiagnostic R&D Department, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JapanSearch for more papers by this authorMorton A. Vodian, Morton A. Vodian T Cell Sciences, Inc., Cambridge, MassachusettsSearch for more papers by this authorPatrick C. Kung, Patrick C. Kung T Cell Sciences, Inc., Cambridge, MassachusettsSearch for more papers by this author First published: 1992 https://doi.org/10.1002/jcla.1860060615Citations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Reinherz EL, Schlossman SF: The differentiation and function of human T lymphocytes. Cell 19: 821–827, 1980. 2 Crabtree GR: Contingent genetic regulatory events in T lymphocyte activation. Science 243: 355–361, 1989. 3 Cotner T, Williams JM, Christenson JL, et al.: Simultaneous flow cytometric analysis of human T-cell activation antigen expressson and DNA content. J Exp Med 157: 461–472, 1983. 4 Morgan RA, Ruscetti FW, Gallo RC: Selective in vitro growth of T lymphocytes. Science 193: 1007–1008, 1976 5 Smith KA: Interleukin-2: Inception, impact and implications. Science 240: 1169–1176, 1988. 6 Taniguchi T, Matsui H, Fujita T, et al.: Structure and expression of cloned cDNA for human interleukin-2. Nature 302: 305–310, 1983. 7 Waldmann TA: The structure and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232: 727–732, 1986. 8 Leonard WJ, Depper JM, Crabtree GR, et al.: Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311: 626–631, 1984. 9 Nikaido T, Shimuzu A, Ishida N, et al.: Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature 311: 631–636, 1984. 10 Cosman D, Ceretti DP, Larsen A, et al.: Cloning, sequence and expression of human interleukin-2 receptor. Nature 312: 768–771, 1984. 11 Hatakeyama M, Tsudo M, Minamoto S, et al.: Interleukin-2 receptor β chain gene: Generation of 3 receptor forms by cloned human α and β chain cDNA's. Science 244: 551–560, 1989. 12 Rubin LA, Kurman CC, Fritz ME, et al.: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172–3177, 1985. 13 Wang HM, Smith KA: The interleukin 2 receptor: Functional consequences of its biomolecular structure. J Exp Med 166: 1055–1069, 1987. 14 Rubin LA, Jay G, Nelson DL: The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 137: 381–384, 1986. 15 Robb RJ, Kutny RM: Structure-function relationships for the IL-2 receptor system. J Immunol 139: 855–862, 1987. 16 Rubin LA, Galli F, Greene WC, Nelson DL, Jay G: The molecular basis for the production of the soluble interleukin-2 receptor. Cytokine 2: 330–336, 1990. 17 Hakimi J, Seals C, Anderson LE, et al.: Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. J Biol Chem 262: 17336–1741, 1987. 18 Loughnan MS, Sanderson CJ, Nossal GJ: Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 2. Proc Natl Acad Sci USA 85: 3115–3119, 1988. 19 Miedel MC, Hulmes JD, Weber DV, Bailon P, Pan YC: Structural analysis of recombinant soluble interleukin-2 receptor. Biochem Biophys Res Commun 154: 372–379, 1988. 20 Yasuda N, Lai PK, Ip SH, et al.: Soluble IL-2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71: 1021–1026, 1988. 21 Jung LK, Hara T, Fu SM: Detection adn functional studies of p60–65 (tac antigen) on activated human B cells. J Exp Med 160: 1597–1602, 1984. 22 Honda M, Kitamura K, Matsuda K, et al.: Soluble IL-2 receptor in AIDS. Correlation of its serum level with the classification of HIV-induced ideases and its characterization. Immunol 142: 4248–4255, 1989. 23 Tsukada N, Matsuda M, Miyagi K, Aoki K. Soluble interleukin-2 receptor in the serum of multiple sclerosis patients. J Med Pharm Sci 24: 1531–1532, 1990. 24 Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K: Soluble interleukin-2 receptors in patients with systemic sclerosis: clinical and laboratory correlations. Arthritis Rheum 33: 375–380, 1990. 25 Ishibashi K, Ishituka K, Ueda H, Mishige Y, Yamauchi K, Chuman Y, Shimotakahara S, Nakahara K, Shimoide Y, Uozumi K, Saito T, Makino T, Iwahashi M, Utsunomiya A, Hanada S, Arima T: sIL-2R in patients with ATL of HTLV-1 carriers. J Med Pharmacol Sci 24: 1205–1210, 1990. 26 Momita S, Ikeda S, Yanagisako T, Atogami S, Mori H, Yamada Y, Kamihira S, Tomonaga M: Serum soluble-interleukin-2 receptor (sIL-2R) in patients with adult T-cell leukemia-lymphoma (ATLL)> J Med Technol 35: 87–91, 1991. 27 Korsemeyer SJ, Greene WC, Cossman J, et al.: Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci USA 80: 4522–4526, 1983 28 Nishiimura Y, Yamaguchi K, Takastuki K: Soluble interleukin-2-receptors levels in various stages from HTLV-I infection to ATL leukaemogenesis. Rinsyo Byori. 37: 333–335, 1989. 29 Marcon L, Rubin LA, Kurman CC, et al.: Elevated serum levels of soluble Tac peptide adult T-cell leukemia: Correlation with clinical status during chemotherapy. Ann Intern Med 109: 274–279, 1988. 30 Chilosi M, Semenzato G, Cetto G, et al.: Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: Relationship with the effects of recombinant α-interferon therapy on lcinical parameters and natural killer in vitro activity. Blood 70: 1530–1553, 1987. 31 Steis RG, Marcon L, Clark J, et al.: Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 71: 1304–1309, 1988. 32 Ho AD, Grossmann M, Knauf W, et al.: Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectromy and with clinical response to therapy. Leukemia 3: 718–723, 1989. 33 Pizzolo G, Chilosi M, Vinante F, et al.: Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer 55: 427–428, 1987. 34 Harrington DS, Patil K, Lai PK, et al.: Soluble interleukin 2 receptors in patients with malignant lymphoma. Arch Pathol Lab Med 112: 597–601, 1988. 35 Matsuzaki H, Asou H, Kawaguchi Y, Hata H, Yoshinaga T, Kinuwaki E, Ishii T, Yamaguchi K, Takatsuki K: Human T-cell leukemia virus type I associated with small cell lung cancer. Cancer 66: 1763–1768, 1990. 36 Barron KS, Montalvo JF, Saadek CK, Orson FM: The usefulness of measuring soluble interleukin-2 receptors in children with Kawasaki syndrome. Arthritis Rheum 31: S77, 1988. 37 Griffin DE, Ward BJ, Jauregui E, Johson RT, Vaisberg A: Immune activation in measles. N Engl J Med 320: 1667–1672, 1989. 38 Boutin B, Matsuguchi L, Lebon P, Ponsot G, Arthurs M, Nelson DL: Soluble IL-2 receptors in acute and subacute encephalitis. Ann Neurology 22: 658–661, 1987. 39 Symons JA, Wood NC, Di Giovine FSD, Duff GW: Soluble IL-2 receptor in rheumatoid arthritis: Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 141: 2612–2618, 1988. 40 Wood NC, Symons JA, Duff GW: Serum interleukin-2-receptor in rheumatoid arthritis: A prognostic indicator of disease activity? A Autoimmun 1: 353–361, 1988. 41 Keystone EC, Snow KM, Bombardier C, Chang C, Nelson DL, Rubin LA: Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 31: 844–849, 1988. 42 Campen DH, Horwitz DA, Quismorio FP, Jr. Ehresmann GR, Martin WJ: Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 31: 1358–1364, 1988. 43 Goto M, Matsura N, Nakajima A, Yamada T, Nishioka K. An investigation of serum soluble IL-2R in the rheumatic disease patients. J Med Pharm Sci 24: 1216–1220, 1990. 44 Shimoide Y, Ishibashi K, Otsuka M, Maeda E, Shou Y, Baba Y, Sugiyasu T, Miura T, Tsubouchi H, Arima T, Fukuda T, Fujisaki K, Sakurami T: Soluble interleukin-2 receptor in the sera of patients with rheumatoid arthritis. J Med Pharm Sci 24: 1521–1524, 1990. 45 Tokano T, Koyashi S, Hashimoto H, Okumura K, Hirose S: A study on the soluble IL-2R as a disease monitoring marker of rheumatoid arthritis. J Med Pharmacol Sci 25: 1713–1717, 1991. 46 Tanaka S, Watanabe N, Nishioka K. Serum-soluble interleukin-2 receptor levels in juvenile rheumatoid arthritis. J Med Pharmacol Sci 24: 1221–1226, 1990. 47 Tokano Y, Sekigawa I, Hashimoto H, Okumura K, Horise S. Soluble interleukin-2 receptor in sera of aptients with systemic lupus erythematosus. Jpn J Clin Immunol 11: 559–565, 1988. 48 Tokano Y, Murashima A, Takasaki Y, Hashimoto H, Okumura K, Horise S: Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis 48: 803–809, 1989. 49 Tokano Y, Hashimoto H, Okumura K, Hirose S: A possible diagnostic value of soluble IL-2R in the serum of rheumatic patients. J Med Pharmacol Sci 24: 1211–1215, 1990. 50 Sawada A, Iijima S, Hayama T, Nishinarita S, Horie T: Soluble interleukin 2 receptor with solid phase enzyme linked immunoassay in patients with systemic lupus erythematosus. J Med Pharmacol Sci 24: 1525–1530, 1990. 51 Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA: A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells and on one of two types of helper T cells. J Immunol 126: 1398, 1981. 52 Nelson DL, Rubin LA, Kurman CC, Fritz ME, Boutin B: An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol. 6: 114, 1986. 53 Hemler ME, Brenner MB, McLean JM, Strominger JL: Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells. Proc Natl Acad Sci USA 81: 2172, 1984. 54 Ryffel B, Tammi K, Grieder A, Hewss AD: Effects of cyclosporine on human T cell activation. Transplant Proc 17: 1269, 1985. 55 Harold KC, Lancki DW, Moldwin RL, Fitch FW: Immunosuppressive effects of cyclosporine a on cloned T cells. J Immunol 136: 1315, 1986. 56 Solbach W, Heek K, Von Steldern U, Rollinghoff M, Wagner H: On the partial suppression of IL-2 receptor expression and the prevention of lectin-induced lymphoblast formation by cyclosporine A. Clin Exp Immunol 60: 501, 1987. 57 Roodman ST, Miller LW, Tsai CC: Role of interleukin 2 receptors in immunologic monitoring following cardiac transplantation. Transplantation 45: 1050–1056, 1988. 58 Mohring, Pomer S, Daniel U, Rambausek M: Interleukin-2 receptor positive cell levels in cyclosporine-versus Azathioprine-treated renal transplant patinets. Trans Proc 21: 1469, 1989. 59 Lawrence E, Holland VA, Young JB, Windsor NT, Brousseau KP, Noon GP, Whisennand HH, Debakey ME, Nelson DL: Dynamic changes in soluble interleukin-2 receptor levels after lung of heart-lung transplantation. Am Rev Respir Dis 140: 789–796, 1989. 60 Colvin RB, Preffer FI, Fuller TC, Brown MC, IP Sh, Kung PC, Cosimi AB: A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation 48: 800–804, 1989. 61 Cornaby AJ, Simpson MA, Madras PN, Dempsey RA, Clowes GHA, Monaco AP: Pre-operative interleukin 2 and interleukin 2 receptor levels may predict susequent renal allograft rejetion. Trans Proc 21: 1861–1862, 1989. 62 Perkins JD, Nelson DL, Rakela J, Grambsch PM Krom RAF: Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation 47: 77–81, 1989. 63 Adams DH, Wang L, Hubscher SG, Elias E: Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet 1: 469–471, 1989. 64 Perkins JD, Munn SR, Barr D, Ferguson DC, Carpenter HA: Evidence that the soluble interleukin-2 recetor level may determine the optimal time for cy/toscopically-drected bipsy in pancraticoduodenal allograft recipients. Transplantation 49: 363–366, 1990. 65 Nelson DL, Wagner DK, Marcon L, et al.: An analysis of soluble IL-2 receptors in human neoplastic disorders. In: A. Albertini, C. Lentant, R. Poeletti, eds. Biotechnology in Clinical Medicine. New York: Raven Press: 227–86, 1987. 66 Uchiyama T, Border S, Waldmann TA. A monoclonal antibody (antiTac) reactive with activated and functional mature human T cells. I. Production of anti-Tac monoclonal natibody and distribution of Tac(+) cells. J. Immunol 126: 1393–97, 1981. 67 Waldmann TA, Greene WC, Sarin PS, et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac. J. Clin INvest. 73: 1711–8, 1984. 68 Pizzolo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol 67: 377–80, 1987. 69 Sugimoto M, Nakashima H, Matsumoto M, Uyama E, Ando M, Araki S. Pulmonry involvement in patients with HTLV-I-associated myelopathy increased soluble IL-2 receptors in bronchoalveolar lavage fluid. Am Rev Respir Dis 139: 1329–35, 1989. 70 Wagner DK, Kiwanuka J, Edwards BK, Rubin LA, et al. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 5: 1262–1274, 1987 71 Pui CH, Ip SH, Kung P, Dodge RK, et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-hodgkin's lymphoma. Blood 70: 624–628, 1987. 72 Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-γ in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56: 29–36, 1990. 73 Matsubara T, Motohashi T, Tsuji K, Furukawa S. Soluble interleukin 2 receptor level in the serum of Kawasaki disease. J Med Pharm Sci 24: 1227–1230, 1990. Citing Literature Volume6, Issue61992Pages 423-436 ReferencesRelatedInformation